Alnylam Pharmaceuticals | La Marge Brute Sur Les Ventes



Gross Profit On Sales Changement Date
Acadia Pharmaceuticals USD 237.8M 72.86M 2024-12
Agios Pharmaceuticals USD 7.64M 1.83M 2025-03
Alnylam Pharmaceuticals USD 523.15M 32.8M 2025-03
Amgen USD 5.54B 430M 2025-03
Arrowhead Research -173085000 2.55M 2024-12
BioMarin Pharmaceutical USD 593.59M 17.59M 2025-03
Incyte USD 985.09M 111.22M 2025-03
Ionis Pharmaceuticals USD 130.15M 92.6M 2025-03
Moderna USD 17M 403M 2025-03
Neurocrine Biosciences USD 618.4M 4.3M 2024-12
Novartis USD 10.24B 313M 2024-12
PTC Therapeutics USD 196.89M 10.95M 2024-12
Regeneron Pharmaceuticals USD 2.56B 659.4M 2025-03
Sanofi EUR 5.36B 4.71B 2024-12
Sarepta Therapeutics USD 526.11M 150.63M 2024-12
Takeda JPY 727.25B 54.48B 2024-12
Ultragenyx Pharmaceutical USD 147.98M 29.51M 2024-12
Vertex Pharmaceuticals USD 2.49B 109.3M 2024-12
Xencor -45143000 40.69M 2024-09



Alnylam Pharmaceuticals La Marge Brute Sur Les Ventes - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - May 2025.